Unlocking the potential of monoclonal antibodies
An experimental Alzheimer’s drug hailed as a breakthrough has slowed cognitive decline in people with the disease at an early stage, according to a new study published in the New England Journal of Medicine. The drug, lecanemab, is a monoclonal antibody – or mAb for short – designed to eliminate amyloid plaques in the brain …
Unlocking the potential of monoclonal antibodies Read More »